RT Journal Article
SR Electronic
T1 Neurologic outcomes in people with multiple sclerosis treated with immune checkpoint inhibitors for oncologic indications
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.13.24308608
DO 10.1101/2024.06.13.24308608
A1 Quinn, Carson M.
A1 Rajarajan, Prashanth
A1 Gill, Alexander
A1 Kopinsky, Hannah
A1 Wolf, Andrew B.
A1 De Camargo, Celeste Soares
A1 Lamb, Jessica
A1 Bacon, Tamar
A1 Murray, Joseph
A1 Probasco, John C.
A1 Galetta, Kristin
A1 Kantor, Daniel
A1 Coyle, Patricia K.
A1 Bhise, Vikram
A1 Alvarez, Enrique
A1 Conway, Sarah
A1 Bhattacharyya, Shamik
A1 Kister, Ilya
YR 2024
UL http://medrxiv.org/content/early/2024/06/13/2024.06.13.24308608.abstract
AB Objective To assess the prevalence of multiple sclerosis (MS) activity, as well as neurologic and non-neurologic immune-related adverse events (irAEs) in persons with MS (pwMS) treated with immune checkpoint inhibitors (ICIs) for cancer.Background ICIs are associated with irAEs and exacerbation of certain preexisting autoimmune diseases. PwMS are generally excluded from ICI clinical trials, so data on the safety of these drugs in pwMS is limited.Design/Methods Participating sites were recruited through the Medical Partnership 4 MS+ (MP4MS+) listserv. Seven large academic centers participated in the study, each conducting a systematic search of their electronic medical record system for patients with MS and ICI exposure. Demographics and data on MS and cancer history, treatments, and outcomes were abstracted from patient charts using a structured instrument.Results We identified 66 pwMS (median age 66 years, 73% female, 68% not on disease-modifying therapy (DMT) for MS) who were treated with ICIs for lung cancers (35%), melanoma (21%) or other oncologic indications. During post-ICI follow-up (median: 11.7 months, range 0.2-106.3 months), two pwMS (3%) had relapse or MRI activity, three (5%) had neurologic irAEs, and 21 (32%) had non-neurologic irAEs. At the last follow-up, 25 (38%) subjects had partial or complete remission of their cancer while 35 (53%) were deceased.Conclusions In this multi-institutional systematic retrospective study of predominantly older pwMS who were off DMTs, MS activity and neurologic irAEs following ICI treatment were rare, suggesting that preexisting MS should not preclude the use of ICIs.Competing Interest StatementDr Kantor reported personal fees from Viatris and an institutional research grant from Bristol Myers Squibb outside the submitted work. Dr. Kantor is the Co-Medical Director of the CorEvitas MS registry, in partnership with the National MS Society and the Founding President of the Medical Partnership 4 MS+ (MP4MS+). All other authors report no relevant disclosures. Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB's of the following institutions gave ethical approval for this work: Mass General Brigham (Boston, MA), University of Colorado School of Medicine (Aurora, CO), Johns Hopkins Medicine (Baltimore, MD), Stanford University Medical Center (Palo Alto, CA), New York University Grossman School of Medicine (New York, NY), Stony Brook Medical Center (Stony Brook, NY), and Robert Wood Johnson Medical Rutgers (Newark, NJ).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesDeidentified data produced in the present study are available upon reasonable request to the authors